Would you like to contribute to this site?
Arthritis Menu
Submit an Article
Submit a Tip
Place your Ad
Add URL
Arthritis Questions?
Contact Us
Related Topics:
Anklosing Spondylitis
Ankylosing Spondalitis
Ankylosing Spondilitis
Ankylosing Spondylitis
Ankylosing Spondylitis Arthritis
Ankylosing Spondylitis Diagnosis
Ankylosing Spondylitis Diet
Ankylosing Spondylitis Disease
Ankylosing Spondylitis Medication
Ankylosing Spondylitis Research
Ankylosing Spondylitis Treatment
Remicade Ankylosing Spondylitis
What Is Ankylosing Spondylitis
Other Channels:
|
 |
|
|
|
|
|
|
|
|
Recent Questions and Answers
|
|
|
|
|
|
|
|
Recent Ankylosing Spondylitis Arthritis News:
|
|
|
VIMOVO is approved for the relief of the signs and symptoms of osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS) and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated ...
Chang-Miller's primary field is rheumatology with special interests in inflammatory joint diseases called seronegative spondyloarthropathies such as ankylosing spondylitis and psoriatic arthritis. She also cares for patients with rheumatoid arthritis ...
Chang-Miller's primary field is rheumatology with special interests in inflammatory joint diseases called seronegative spondyloarthropathies such as ankylosing spondylitis and psoriatic arthritis. She also cares for patients with rheumatoid arthritis ...
... AstraZeneca following FDA’s recent approval of Vimovo™ delayed-release tablets for relieving the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis and for decreasing the risk of NSAID-related gastric ...
... prevalence of rheumatoid arthritis was 0.58 per cent (95 per cent confidence interval [CI], 0.32-0.87), of psoriatic arthritis was 0.35 per cent (95 CI, 0.33-1.13), of ankylosing spondylitis was 0.29 per cent (95 CI, 0.28-0.94), of primary ...
| |
| |
|
|
|
Additional Ankylosing Spondylitis Arthritis Resources:
|
|
|
|
|
|
|
|
|
Want your site featured on this page?
|
|
 |
|